Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 4/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfisomidine SCHEMBL34791 | 0.80 | PDE4A (1.00) | ALDH1A1LMNAKDM4EPDE4AAGO2 | |
| SCHEMBL1828300 | 0.80 | PDE4A (0.74) | ALDH1A1LMNAKDM4EPDE4AAGO2 | |
| SCHEMBL1381858 | 0.80 | PDE4A (0.73) | ALDH1A1LMNAKDM4EPDE4AAGO2 | |
| Sulfisomidine SCHEMBL284793 | 0.79 | PDE4A (0.97) | ALDH1A1LMNAKDM4EPDE4AAGO2 | |
| SCHEMBL10031598 | 0.79 | MEN1 (0.70) | ALDH1A1LMNAKDM4EPOLBUSP2 | |
| SCHEMBL11757838 | 0.77 | PDE4A (0.69) | ALDH1A1LMNAKDM4EPDE4AAGO2 | |
| SCHEMBL12464128 | 0.77 | POLB (0.66) | ALDH1A1LMNAKDM4EPDE4AAGO2 | |
| SCHEMBL21637832 | 0.77 | USP2 (0.71) | ALDH1A1LMNAKDM4EPOLBUSP2 | |
| SCHEMBL10031587 | 0.76 | POLB (0.68) | ALDH1A1LMNAKDM4EPOLBUSP2 | |
| SCHEMBL12010926 | 0.76 | HSD11B1 (0.68) | ALDH1A1LMNAKDM4EPDE4AAGO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993117-B2 | Devices with multiple surface functionality | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-03-31 | — | — | US | claimed |
| US-20120121661-A1 | DEVICES WITH MULTIPLE SURFACE FUNCTIONALITY | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-05-17 | — | — | US | claimed |
| US-12508349-B2 | Apparatuses and methods for treating ophthalmic diseases and disorders | BIOTISSUE HOLDINGS INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12492392-B2 | Histidyl-tRNA synthetase-Fc conjugates and therapeutics using the same | ATYR PHARMA, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250009557-A1 | INTRAOCULAR DRUG DELIVERY | AQUESYS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20240398760-A1 | CHELATED, STABLE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE AND APPLICATIONS THEREOF | SOMERSET THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
| US-12102632-B2 | Quinolone dispersions | SOMERSET THERAPEUTICS, LLC (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4420689-A2 | A DEVICE | Keighleycolo Ltd (GB) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024163315-A2 | DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS | DEVORE DALE (US) | 2024-08-08 | — | — | WO | disclosed |
| US-20240252446-A1 | DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS | SUSTAINED DRUG DELIVERY LLC | 2024-08-01 | — | — | US | disclosed |
| US-12029729-B2 | Chelated, stable ophthalmological compositions of ketorolac and phenylephrine and applications thereof | SOMERSET THERAPEUTICS, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| EP-1579198-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | Transform Pharmaceuticals, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050208094-A1 | Bone cement compositions having fiber-reinforcement and/or increased flowability | SYNTHES USA, LLC | 2005-09-22 | — | — | US | disclosed |
| CN-1668283-A | Pharmaceutical composition with improved dissolution | TRANSFORM PHARMACEUTICALS INC (US) | 2005-09-14 | — | — | CN | disclosed |
| WO-2005032417-A2 | ANTIMICROBIAL HYALURONIC ACID COATINGS FOR ORTHOPEDIC IMPLANTS | SYNTHES (USA) (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1515703-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | Transform Pharmaceuticals, Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20050025791-A1 | Pharmaceutical compositions with improved dissolution | TRANSFORM PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2004061433-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004026235-A2 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004000284-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102632-B2 | Quinolone dispersions | F12, CFD, NFKBIA | ALDH1A1 2660/4885LMNA 2333/4885KDM4E 3204/4885 |
| US-12029729-B2 | Chelated, stable ophthalmological compositions of ketorolac and phenylephrine and applications thereof | CRYZ, UACA, MYOC | ALDH1A1 3291/4885LMNA 2112/4885KDM4E 618/4885 |
| US-20050025791-A1 | Pharmaceutical compositions with improved dissolution | ABCG2, SI, SLC10A2 | ALDH1A1 3899/4885LMNA 4001/4885KDM4E 3912/4885 |
| US-20240398760-A1 | CHELATED, STABLE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE AND APPLICATIONS THEREOF | CRYZ, UACA, MYOC | ALDH1A1 3291/4885LMNA 2112/4885KDM4E 618/4885 |
| US-12508349-B2 | Apparatuses and methods for treating ophthalmic diseases and disorders | PGF, FSCN1, CSTB | ALDH1A1 751/4885LMNA 1160/4885KDM4E 4381/4885 |
| US-20120121661-A1 | DEVICES WITH MULTIPLE SURFACE FUNCTIONALITY | PHOSPHO1, CD44, SELP | ALDH1A1 2513/4885LMNA 4659/4885KDM4E 2309/4885 |
| US-12492392-B2 | Histidyl-tRNA synthetase-Fc conjugates and therapeutics using the same | AARS1, HARS1, GARS1 | ALDH1A1 3157/4885LMNA 3723/4885KDM4E 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.